BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 8001024)

  • 1. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias.
    McGraw KJ; Rosenblum MG; Cheung L; Scheinberg DA
    Cancer Immunol Immunother; 1994 Dec; 39(6):367-74. PubMed ID: 8001024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice.
    Xu Y; Xu Q; Rosenblum MG; Scheinberg DA
    Leukemia; 1996 Feb; 10(2):321-6. PubMed ID: 8637241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel.
    Duzkale H; Pagliaro LC; Rosenblum MG; Varan A; Liu B; Reuben J; Wierda WG; Korbling M; McMannis JD; Glassman AB; Scheinberg DA; Freireich EJ
    Biol Blood Marrow Transplant; 2003 Jun; 9(6):364-72. PubMed ID: 12813444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity.
    Pagliaro LC; Liu B; Munker R; Andreeff M; Freireich EJ; Scheinberg DA; Rosenblum MG
    Clin Cancer Res; 1998 Aug; 4(8):1971-6. PubMed ID: 9717827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity.
    Caron PC; Jurcic JG; Scott AM; Finn RD; Divgi CR; Graham MC; Jureidini IM; Sgouros G; Tyson D; Old LJ
    Blood; 1994 Apr; 83(7):1760-8. PubMed ID: 8142644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies.
    Caron PC; Co MS; Bull MK; Avdalovic NM; Queen C; Scheinberg DA
    Cancer Res; 1992 Dec; 52(24):6761-7. PubMed ID: 1458463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia.
    Caron PC; Schwartz MA; Co MS; Queen C; Finn RD; Graham MC; Divgi CR; Larson SM; Scheinberg DA
    Cancer; 1994 Feb; 73(3 Suppl):1049-56. PubMed ID: 8306247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.
    Jurcic JG; Caron PC; Nikula TK; Papadopoulos EB; Finn RD; Gansow OA; Miller WH; Geerlings MW; Warrell RP; Larson SM
    Cancer Res; 1995 Dec; 55(23 Suppl):5908s-5910s. PubMed ID: 7493368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies.
    Borthakur G; Rosenblum MG; Talpaz M; Daver N; Ravandi F; Faderl S; Freireich EJ; Kadia T; Garcia-Manero G; Kantarjian H; Cortes JE
    Haematologica; 2013 Feb; 98(2):217-21. PubMed ID: 22875630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia.
    Robertson MJ; Soiffer RJ; Freedman AS; Rabinowe SL; Anderson KC; Ervin TJ; Murray C; Dear K; Griffin JD; Nadler LM
    Blood; 1992 May; 79(9):2229-36. PubMed ID: 1571539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
    Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
    Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.
    Hamann PR; Hinman LM; Hollander I; Beyer CF; Lindh D; Holcomb R; Hallett W; Tsou HR; Upeslacis J; Shochat D; Mountain A; Flowers DA; Bernstein I
    Bioconjug Chem; 2002; 13(1):47-58. PubMed ID: 11792178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells.
    Schwemmlein M; Peipp M; Barbin K; Saul D; Stockmeyer B; Repp R; Birkmann J; Oduncu F; Emmerich B; Fey GH
    Br J Haematol; 2006 Apr; 133(2):141-51. PubMed ID: 16611304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance of myeloid leukaemia cell lines to ricin A-chain immunotoxins.
    Engert A; Brown A; Thorpe P
    Leuk Res; 1991; 15(11):1079-86. PubMed ID: 1961012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs.
    Nguyen DH; Ball ED; Varki A
    Exp Hematol; 2006 Jun; 34(6):728-35. PubMed ID: 16728277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia.
    Caron PC; Lai LT; Scheinberg DA
    Clin Cancer Res; 1995 Jan; 1(1):63-70. PubMed ID: 9815888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies.
    Bolognesi A; Tazzari PL; Olivieri F; Polito L; Lemoli R; Terenzi A; Pasqualucci L; Falini B; Stirpe F
    Br J Haematol; 1998 Apr; 101(1):179-88. PubMed ID: 9576199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2.
    Mujoo K; Reisfeld RA; Cheung L; Rosenblum MG
    Cancer Immunol Immunother; 1991; 34(3):198-204. PubMed ID: 1756537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias.
    Virgo P; Denning-Kendall PA; Erickson-Miller CL; Singha S; Evely R; Hows JM; Freeman SD
    Br J Haematol; 2003 Nov; 123(3):420-30. PubMed ID: 14617000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.
    Matsui H; Takeshita A; Naito K; Shinjo K; Shigeno K; Maekawa M; Yamakawa Y; Tanimoto M; Kobayashi M; Ohnishi K; Ohno R
    Leukemia; 2002 May; 16(5):813-9. PubMed ID: 11986941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.